Study of LINC0046 in EGFR mutation-positive lung cancer using circulating tumor cells

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K08169
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53030:Respiratory medicine-related
• Research Institution: Toho University
• Principal Investigator: Isobe Kazutoshi 東邦大学, 医学部, 准教授 (70385607)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 原発生肺癌 / EGFR遺伝子変異 / long non-coding RNA / LINC00460

Outline of Final Research Achievements

Long non-coding RNA LINC00460 has been reported to be associated with epithelial-mesenchymal transition and promotion of tumor motility in lung cancer, and we evaluated LINC00460 expression in 54 samples (RNA extracted from tumor tissues in 30 cases and plasma-free RNA in 24 cases) obtained from lung cancer patients with EGFR mutation. In examining 30 cases from which tumor tissues were extracted and 24 cases from which plasma cell-free RNA was extracted, we found that LINC00460 expression was not significantly correlated with clinical stage, and that patients with high LINC00460 expression tended to have a lower therapeutic effect of osimertinib and a shorter prognosis compared to those with low LINC00460 expression.

Free Research Field

呼吸器内科

Academic Significance and Societal Importance of the Research Achievements

本研究により、EGFR遺伝子変異陽性肺癌患者のLINC00460の発現亢進は、オシメルチニブで治療された患者の予後不良因子であることが確認された。これらの研究は血液検体や腫瘍組織を用いた確実なサンプリングに基づいた個別化治療のシステム構築に寄与し、LINC00460の有無を層別化因子とした原発性肺癌の個別化治療法の確立に大きく貢献するものと考えられる。